Jazz Pharmaceuticals plc (JAZZ) Form 10-Q — Aug 3, 2026
Jazz Pharmaceuticals reported strong financial results for the six months ended June 30, 2026, with total revenues increasing 17% to $2.28 billion compared to the prior year period. The company swung to a net income of $485.9 million, or $7.17 per diluted share, reversing a net loss of $811.0 million in the same period of 2025, driven by robust product sales growth and the absence of significant one-time charges like the prior year's acquired in-process research and development expense. Commercial performance was led by Xywav, which grew 16% to $879.4 million, and Zepzelca, which surged 50% to $206.8 million following its approval for first-line maintenance in small cell lung cancer.
Key figures
- Eps
- 7.17
- Net Income
- 485.9
- Total Debt
- 4395
- Revenue Growth
- 17%
- Debt repaid
- 1000
- Prv proceeds
- 200
- Xywav revenue 6m
- 879.4
- Modeyso revenue 6m
- 89.6
- Zepzelca revenue 6m
- 206.8
- Xywav revenue growth 6m
- 16%
Price after filing
Close on the filing date to close N calendar days later (from $258.38). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.